Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE LPF versus XATMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE LPF versus XATMEP.
METHOTREXATE LPF vs XATMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the synthesis of tetrahydrofolate and subsequently thymidylate and purine synthesis. This inhibits DNA synthesis, repair, and cellular replication. In low-dose regimens, it has anti-inflammatory and immunomodulatory effects through adenosine release and inhibition of cytokine production.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, blocking the synthesis of tetrahydrofolate and thereby inhibiting DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through inhibition of purine metabolism and adenosine accumulation.
7.5 to 25 mg orally once weekly for rheumatoid arthritis; for psoriasis, 10 to 25 mg orally once weekly. Intravenous dosing varies by indication; for high-dose methotrexate (e.g., osteosarcoma), 8 to 12 g/m² IV over 4 hours.
Methotrexate 10 mg orally once weekly; maximum 25 mg per week.
None Documented
None Documented
Terminal half-life 3-10 hours for low doses, 8-15 hours for high doses; prolonged to 12-24 hours in renal impairment due to delayed clearance.
The terminal elimination half-life of methotrexate is approximately 3-10 hours for low doses (<50 mg/m²) and 8-15 hours for high doses (≥500 mg/m²). Prolonged half-life (>24 hours) is associated with renal impairment and drug accumulation, increasing toxicity risk.
Primarily renal (80-90% unchanged via glomerular filtration and active tubular secretion); small amount biliary/fecal (<10%).
Methotrexate is primarily eliminated renally via glomerular filtration and active tubular secretion. Approximately 80-90% of the dose is excreted unchanged in urine within 24 hours. Fecal excretion is minimal (<10%), with biliary elimination accounting for a small fraction.
Category D/X
Category C
Antimetabolite
Antimetabolite